心肾综合征的最新研究进展。
Updates in Cardiorenal Syndrome.
机构信息
Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA 02111, USA.
Division of Cardiovascular Medicine, Yale School of Medicine, PO Box 208017, New Haven, CT 06520, USA.
出版信息
Med Clin North Am. 2023 Jul;107(4):763-780. doi: 10.1016/j.mcna.2023.03.011. Epub 2023 Apr 15.
Abstract
Cardiorenal syndrome is a term that refers to a collection of disorders involving both the heart and kidneys, encompassing multi-directional pathways between the 2 organs mediated through low arterial perfusion, venous congestion, and neurohormonal activation. The pathophysiology is complex and includes hemodynamic and neurohormonal changes, but inconsistent findings from recent studies suggest this is very heterogenous disorder. Management for ADHF remains focused on decongestion and neurohormonal blockade to overcome the intense sodium and fluid avidity of the CRS.
摘要
心脏肾综合征是一个术语，指的是涉及心脏和肾脏的一系列疾病，包括 2 个器官之间通过低动脉灌注、静脉充血和神经激素激活介导的多向途径。其病理生理学较为复杂，包括血流动力学和神经激素变化，但最近的研究结果不一致，表明这是一种非常异质性的疾病。ADHF 的治疗仍然侧重于充血和神经激素阻断，以克服 CRS 对钠和液体的强烈渴望。
相似文献
1
Updates in Cardiorenal Syndrome.
Med Clin North Am. 2023 Jul;107(4):763-780. doi: 10.1016/j.mcna.2023.03.011. Epub 2023 Apr 15.
2
Cardiorenal Syndrome in the Hospital.
Clin J Am Soc Nephrol. 2023 Jul 1;18(7):933-945. doi: 10.2215/CJN.0000000000000064. Epub 2023 Jan 13.
3
Cardiorenal syndrome in acute decompensated heart failure.
Expert Rev Cardiovasc Ther. 2012 Feb;10(2):177-89. doi: 10.1586/erc.11.193.
4
Insights into cardiorenal interactions in acute decompensated heart failure.
Curr Opin Cardiol. 2017 Mar;32(2):203-208. doi: 10.1097/HCO.0000000000000378.
5
Cardiorenal syndrome: Decongestion in heart failure across wide spectrum of kidney pathophysiology.
Adv Clin Exp Med. 2022 Apr;31(4):445-455. doi: 10.17219/acem/144327.
6
Heart-Kidney Interactions in Cardiorenal Syndrome Type 1.
Adv Chronic Kidney Dis. 2018 Sep;25(5):408-417. doi: 10.1053/j.ackd.2018.08.013.
7
RAAS inhibition and cardiorenal syndrome.
Curr Hypertens Rev. 2014;10(2):107-11. doi: 10.2174/1573402111666141231144228.
8
Cardiorenal syndrome.
Heart Fail Clin. 2014 Apr;10(2):251-80. doi: 10.1016/j.hfc.2013.12.003. Epub 2014 Feb 4.
9
Safety and Performance of the Aortix Device in Acute Decompensated Heart Failure and Cardiorenal Syndrome.
JACC Heart Fail. 2023 Nov;11(11):1565-1575. doi: 10.1016/j.jchf.2023.06.018. Epub 2023 Oct 4.
10
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network.
J Card Fail. 2012 Mar;18(3):176-82. doi: 10.1016/j.cardfail.2011.12.009. Epub 2012 Feb 2.
引用本文的文献
1
Cardiorenal Syndrome in the Elderly: Challenges and Considerations.
Geriatrics (Basel). 2025 Aug 4;10(4):104. doi: 10.3390/geriatrics10040104.
2
Acute kidney injury after myocardial infarction: prognostic implications via dual robust methods.
Front Med (Lausanne). 2025 Jul 22;12:1555478. doi: 10.3389/fmed.2025.1555478. eCollection 2025.
3
Prognostic value of dynamic KDIGO staging in acute kidney injury after acute heart failure: a doubly robust analysis.
Sci Rep. 2025 Jul 2;15(1):22920. doi: 10.1038/s41598-025-07118-y.
4
The association of albumin-corrected anion gap and acute kidney injury in heart failure patients: a competing risk model analysis.
BMC Cardiovasc Disord. 2025 Apr 11;25(1):277. doi: 10.1186/s12872-025-04723-7.
5
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.
Cardiovasc Drugs Ther. 2024 Nov 16. doi: 10.1007/s10557-024-07649-y.
6
Ubiquitin-Specific Protease 18 in Chronic Kidney Disease-Another Emerging Biomarker to Consider?
Biomedicines. 2024 May 13;12(5):1073. doi: 10.3390/biomedicines12051073.
本文引用的文献
1
Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR.
Kidney360. 2022 Aug 23;3(10):1807-1814. doi: 10.34067/KID.0003202022. eCollection 2022 Oct 27.
2
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Eur Heart J. 2023 Feb 1;44(5):411-421. doi: 10.1093/eurheartj/ehac689.
3
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
Kidney Int. 2022 Nov;102(5):990-999. doi: 10.1016/j.kint.2022.06.013.
4
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27.
5
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
Eur Heart J. 2022 Nov 1;43(41):4362-4373. doi: 10.1093/eurheartj/ehac401.
6
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
7
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28.
8
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.
Eur J Heart Fail. 2022 Sep;24(9):1591-1598. doi: 10.1002/ejhf.2421. Epub 2022 Jan 18.
9
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.
J Am Soc Nephrol. 2021 Dec 1;32(12):2994-3015. doi: 10.1681/ASN.2021070988.
10
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
Zotero 插件